Phase I Study: Ivosidenib or Enasidenib + Standard Induction Chemotherapy in Newly Diagnosed AML With < i > IDH1/IDH2 < /i > Mutations

Slideset - The combination of IDH inhibitors enasidenib or ivosidenib with standard 7 + 3 induction chemotherapy appears safe with response rates comparable to those expected with standard induction chemotherapy in patients with either de novo or secondary AML.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research